ADMA Biologics Faces Securities Class Action Over Alleged Misconduct

The complaint alleges that ADMA Biologics misled the market by failing to disclose a related party transaction and employing channel stuffing to artificially inflate revenue figures. According to the filing, the company also struggled to maintain adequate internal controls, rendering its public statements throughout the class period materially false and deceptive. Investors who suffered financial losses following the revelation of these practices are encouraged to contact Brian Schall or David Schwartz at the Los Angeles-based firm to discuss potential recovery options.

While the class has not yet been certified, affected shareholders retain the right to participate in the litigation or remain absent class members. The firm emphasizes that individuals do not need to be appointed as lead plaintiff to participate in a potential settlement or recovery. Interested parties can reach the legal team at 310-301-3335 or via their official website to review their rights and participation requirements before the upcoming deadline.